BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarwar A, Zhou L, Novack V, Tapper EB, Curry M, Malik R, Ahmed M. Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States. Hepatology. 2017;. [PMID: 28681542 DOI: 10.1002/hep.29354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, Rowe IA, Roslund N, Ireland H, Lomax M, Leithead JA, Mehrzad H, Aspinall RJ, McDonagh J, Patch D. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020;69:1173-92. [PMID: 32114503 DOI: 10.1136/gutjnl-2019-320221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
2 Tejedor-Tejada J, Fuentes-Valenzuela E, García-Pajares F, Nájera-Muñoz R, Almohalla-Álvarez C, Sánchez-Martín F, Calero-Aguilar H, Villacastín-Ruiz E, Pintado-Garrido R, Sánchez-Antolín G. Long-term clinical outcome and survival predictors in patients with cirrhosis after 10-mm-covered transjugular intrahepatic portosystemic shunt. Gastroenterol Hepatol 2021;44:620-7. [PMID: 33249114 DOI: 10.1016/j.gastrohep.2020.10.018] [Reference Citation Analysis]
3 Keimburg SA, Theysohn J, Buechter M, Rashidi-alavijeh J, Willuweit K, Schneider H, Wetter A, Maasoumy B, Lange C, Wedemeyer H, Markova AA. FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. Biomedicines 2022;10:1018. [DOI: 10.3390/biomedicines10051018] [Reference Citation Analysis]
4 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
5 Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K. Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement. PLoS One 2019;14:e0217442. [PMID: 31120995 DOI: 10.1371/journal.pone.0217442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cannella R, Tselikas L, Douane F, Cauchy F, Rautou P, Duran R, Ronot M. Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100484] [Reference Citation Analysis]
7 Hernández-Gea V, Bureau C. Practice makes better: TIPS procedures in referral centers. Hepatology 2018;67:473-5. [PMID: 28873237 DOI: 10.1002/hep.29507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Charilaou P, Devani K, Petrosyan R, Reddy C, Pyrsopoulos N. Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients. Dig Dis Sci. 2020;. [PMID: 32062714 DOI: 10.1007/s10620-020-06136-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
9 Sturm L, Praktiknjo M, Bettinger D, Huber JP, Volkwein L, Schmidt A, Kaeser R, Chang J, Jansen C, Meyer C, Thomas D, Thimme R, Trebicka J, Schultheiß M. Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt. Hepatol Commun 2021;5:650-60. [PMID: 33860123 DOI: 10.1002/hep4.1654] [Reference Citation Analysis]
10 Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE Jr. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021;298:493-504. [PMID: 33497318 DOI: 10.1148/radiol.2021201960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yeoh SW, Kok HK. Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. J Dig Dis 2021. [PMID: 34323378 DOI: 10.1111/1751-2980.13035] [Reference Citation Analysis]
12 Tandon B, Ramachandran J, Narayana S, Muller K, Pathi R, Wigg AJ. Outcomes of transjugular intrahepatic portosystemic shunt procedures: a 10-year experience. J Med Imaging Radiat Oncol 2021. [PMID: 33687155 DOI: 10.1111/1754-9485.13168] [Reference Citation Analysis]
13 Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. World J Gastroenterol 2019; 25(28): 3738-3752 [PMID: 31391769 DOI: 10.3748/wjg.v25.i28.3738] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
14 Bouzbib C, Cluzel P, Sultanik P, Bernard-Chabert B, Massard J, Benosman H, Mallet M, Tripon S, Conti F, Thabut D, Rudler M. Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era. Clin Res Hepatol Gastroenterol 2021;45:101593. [PMID: 33667917 DOI: 10.1016/j.clinre.2020.101593] [Reference Citation Analysis]
15 Mah JM, DeWit Y, Djerboua M, Menard A, Booth CM, Flemming JA. Association Between Institutional Factors and Long-Term Survival Following Transjugular Intrahepatic Portosystemic Shunt. Hepatol Commun 2019;3:838-46. [PMID: 31168517 DOI: 10.1002/hep4.1345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]